Trial Profile
An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Romyelocel-L (Primary) ; Filgrastim
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Cellerant Therapeutics
- 22 Jun 2021 Primary endpoint (Duration of febrile episodes (fever)) has not been met as per results published in the Journal of Clinical Oncology
- 22 Jun 2021 Results published in the Journal of Clinical Oncology
- 04 Dec 2018 Results from cohorts receiving HIDAC chemotherapy (n=53), presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.